Olink to participate in November investor events
Get Alerts OLK Hot Sheet
Join SI Premium – FREE
UPPSALA, Sweden, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Company management will participate in the following investor events:
- Olink Investor Day 2022Monday, November 14th at 11:00 am ET
- Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumThursday, November 17th at 2:00 pm ET
A live and archived webcast of the Olink Investor Day will be available on the “Events” section of the Company’s website at https://investors.olink.com/news-events/events.
About OlinkOlink Holding AB (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America, and Asia. Olink is headquartered in Uppsala, Sweden.
IR contact Jan Medina, CFAVP Investor Relations & Capital MarketsMobile: +1 617 802 4157[email protected]
Media contact Andrea PranderCorporate Communications ManagerMobile: +46 768 775 275[email protected]
Source: Olink Proteomics AB
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Steelworkers back Canada holding the line on trade, call for a stronger response to protect Canadian jobs and industry
- Crypto Presale Guide: What $BULLSKI’s Published Ladder Actually Fixes
- Pump.fun vs MemeToro vs Four.meme: Which Memecoin Launchpad Could Lead 2026?
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share